On Nov 22, major Wall Street analysts update their ratings for $Kura Oncology (KURA.US)$, with price targets ranging from $18 to $34.
BofA Securities analyst Jason Zemansky maintains with a buy rating, and adjusts the target price from $35 to $29.
Barclays analyst Peter Lawson maintains with a buy rating, and maintains the target price at $32.
Jefferies analyst Roger Song maintains with a buy rating, and adjusts the target price from $32 to $28.
TD Cowen analyst Phil Nadeau maintains with a buy rating.
Mizuho Securities analyst Salim Syed maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Kura Oncology (KURA.US)$'s main analysts recently are as follows:
Kura Oncology has entered a significant development and commercialization agreement with a major partner for its prime project, ziftomenib. The deal, which includes a substantial upfront payment alongside notable near-term milestones, provides Kura with a solid financial foundation to pursue pivotal frontline development. This strategic partnership allows for an extensive and aggressive development plan for ziftomenib, notably in the treatment of acute myeloid leukemia, at a critical period to maximize its commercial potential. Additionally, this agreement mitigates financial risks associated with the company's stock in the short to medium term, while preserving considerable value.
Following Kura Oncology's announcement of a global strategic alliance with Kyowa Kirin for the development and commercialization of ziftomenib, an oral menin inhibitor aimed at treating acute myeloid leukemia and other hematologic malignancies, analysts interpret this deal as strategically advantageous. It provides essential capital to expedite Kura's AML franchise and potentially positions ziftomenib as a leading treatment in its class. Despite an anticipated near-term reduction in the stock's M&A premium, the deal is seen to enhance the company's fundamental value through a strengthened balance sheet and fully funded development in key AML markets.
Here are the latest investment ratings and price targets for $Kura Oncology (KURA.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月22日，多家華爾街大行更新了$Kura Oncology (KURA.US)$的評級，目標價介於18美元至34美元。
美銀證券分析師Jason Zemansky維持買入評級，並將目標價從35美元下調至29美元。
巴克萊銀行分析師Peter Lawson維持買入評級，維持目標價32美元。
富瑞集團分析師Roger Song維持買入評級，並將目標價從32美元下調至28美元。
TD Cowen分析師Phil Nadeau維持買入評級。
瑞穗證券分析師Salim Syed維持買入評級。
此外，綜合報道，$Kura Oncology (KURA.US)$近期主要分析師觀點如下：
kura oncology與一家主要合作伙伴簽訂了一項重要的開發和商業化協議，涉及其主要項目ziftomenib。該交易包括一筆可觀的預付款以及顯著的短期里程碑，爲kura提供了堅實的財務基礎，以追求關鍵的前線開發。這一戰略伙伴關係使得ziftomenib的開發計劃能夠更加廣泛和積極，尤其是在急性髓系白血病的治療上，在一個關鍵時期以最大化其商業潛力。此外，這一協議降低了與公司股票在短期至中期相關的財務風險，同時保留了相當的價值。
在kura oncology宣佈與Kyowa Kirin建立全球戰略聯盟，以開發和商業化ziftomenib（一種旨在治療急性髓系白血病及其他血液惡性腫瘤的口服menin抑制劑）後，分析師認爲這筆交易具有戰略優勢。它爲加快kura的急性髓系白血病品牌提供了必要的資金，可能使ziftomenib成爲其類別中的領先治療。儘管預計短期內股票的併購溢價將減少，但這一交易被視爲通過增強的資產負債表和在關鍵的急性髓系白血病市場完全融資的開發，提升了公司的基本價值。
以下爲今日10位分析師對$Kura Oncology (KURA.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
